Trellus Health PLC
12 August 2026
The information communicated within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the Company's obligations under Article 17 of MAR. Upon the publication of this announcement, this inside information is now considered to be in the public domain.
Trellus Health plc
("Trellus Health", "Company" or "Group")
$50,000 Loan and Related Party Transaction
Trellus Health plc (AIM: TRLS), a healthcare company delivering Trellus Elevate®, a digital platform that integrates data analytics with personalised, scientifically proven resilience programmes and value-based solutions to manage complex chronic conditions, announces that the Company's US operating subsidiary Trellus Health Inc. has entered into an unsecured loan agreement with certain members of the Group's executive management team with a principal amount of US$50,000 (the "Loan"). The Loan includes a US$20,000 participation by Dr. Marla Dubinsky, Chief Executive Officer and Co-Founder. Further to the Company's announcement of 31 July 2026 and following agreement of the Loan, the Board confirms that the Company's cash runway has now been extended to late August 2026.
The Board also updates that discussions with a prospective purchaser regarding the acquisition of certain of the Company's assets, including the shares in Trellus Health Inc., which had reached an advanced stage, have now been discontinued. The Board, in conjunction with its corporate restructuring advisers, is in earlier stage discussions with other potentially interested parties regarding a potential sale of these assets. There can be no certainty that any transaction will be concluded or further funding will be forthcoming nor as to the terms thereon. The Board also continues to take action to protect wider stakeholders' interests.
Loan terms
Interest on the Loan, which is unsecured, will accrue at an annual rate of 5% with effect from the date of first drawdown, payable on maturity of the Loan, which falls due for repayment on the earlier of (i) the close of a transaction related to Trellus Health Inc.; or (ii) 24 September 2026.
Related Party Transaction
The Loan is deemed to be a related party transaction under AIM Rule 13 of the AIM Rules for Companies as Dr. Marla Dubinsky is a director of the Company. The Company's independent directors consider, having consulted with the Company's Nominated Adviser, Singer Capital Markets, that the terms of the related party transaction are fair and reasonable insofar as the shareholders of the Company are concerned. Dr. Marla Dubinsky did not take part in the Board's consideration of the related party transaction, given her participation in the Loan.
The Company's ordinary shares remain suspended from trading on AIM since 8 May 2026 due to the ongoing uncertainty regarding the Company's financial position.
Further announcements will be made as appropriate.
Enquiries:
|
Trellus Health plc |
|
||||
|
Dr. Marla Dubinsky, Chief Executive Officer and Co-Founder |
Via Walbrook PR |
||||
|
Joy Bessenger, Chief Financial Officer |
|||||
|
Singer Capital Markets (Nominated Adviser and Broker) |
|||||
|
Peter Steel |
Tel: +44 (0)20 7496 3000 303 |
||||
|
Walbrook PR |
Tel: +44 (0)20 7933 8780 or trellus@walbrookpr.com |
||||
|
Lianne Applegarth / |
Mob: +44 (0)7584 391 303/ |
||||
|
Alice Woodings |
+44 (0)7407 804 654 |
||||
About Trellus Health plc (www.trellushealth.com)
Trellus Health® (AIM: TRLS) is a healthcare company providing value-based innovative solutions and services, helping people with chronic conditions take control of their health through a proven, scientifically validated self-management solution and continuous, personalised support. Trellus Health's approach empowers patients to better navigate the emotional and physical challenges of their conditions, leading to significant cost savings, enhanced treatment adherence, and long-term, sustainable health outcomes.
Trellus Health® integrates its proprietary resilience-based methodology with the technology, tools, and expert coaching and educator team to deliver Trellus Elevate®, a whole-person technology-enhanced condition management platform. The Company is initially focusing on chronic costly GI conditions that have a high mental health burden, such as Inflammatory Bowel Disease (IBD). Among IBD patients, applying the Trellus Elevate® methodology resulted in over 90% fewer hospitalisations and a reduction of over 70% in emergency room visits. Given the common emotional and mental health struggles associated with a variety of chronic conditions and therapeutic areas, Trellus Health® considers its approach to have potential utility and demand across many conditions.
The Company also offers Trellus TrialSet™, a solution for pharmaceutical partners spanning clinical trials to commercialisation, applying the same validated resilience science and platform to support trial success and long-term patient engagement
The Company was founded by Icahn School of Medicine at Mount Sinai faculty members Marla C. Dubinsky, MD, and Laurie Keefer, PhD, both world-leading experts in treating both the physical and emotional impacts of IBD, with a combined 50 years of pioneering whole-person healthcare innovation.
Shares in Trellus Health were admitted to trading on AIM in May 2021, under the ticker TRLS. For more information, visit: www.trellushealth.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
ENDRNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.